Novo Nordisk on Friday raised its outlook for its full-year gross sales and working revenue as a consequence of hovering demand for its blockbuster weight reduction drug Wegovy and diabetes therapy Ozempic.
The revised forecast solely confirms the frenzy for these weekly injections, which sufferers search for his or her means to assist them lose important weight over time. Ozempic and Wegovy have propelled Novo Nordisk to develop into Europe’s Most worthy firm.
The Danish drugmaker now expects 2023 gross sales development in native currencies of 32% to 38%, from a earlier outlook of 27% to 33%, in keeping with a press launch.
Novo Nordisk additionally expects working revenue development of 40% to 46%, from 31% to 37% beforehand.
The brand new gross sales outlook for this 12 months primarily displays greater expectations for Ozempic gross sales within the U.S. and “gross-to-net gross sales changes for Ozempic and Wegovy within the U.S.,” in keeping with the discharge.
Novo Nordisk is slated to report third-quarter earnings Nov. 2.
The corporate’s U.S.-listed shares rose about 1% and touched a brand new 52-week excessive Friday.
An Ozempic injection pen is seen on a kitchen desk in Riga, Latvia, on Aug. 6, 2023.
Jaap Arriens | Nurphoto | Getty Photos
